^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    1d
    COMPEL: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
    1d
    ORIGIN2: Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Swiss Cancer Institute | Trial completion date: Mar 2029 --> Jul 2029 | Initiation date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2028 --> Jul 2028
    Trial completion date • Trial initiation date • Trial primary completion date • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    gemcitabine • Yidafan (ivonescimab)
    2d
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)
    3d
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Pfizer | N=53 --> 162
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    3d
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) (clinicaltrials.gov)
    P3, N=750, Recruiting, Amgen | Trial completion date: Jun 2031 --> Jun 2032 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)
    3d
    Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy (clinicaltrials.gov)
    P1/2, N=32, Not yet recruiting, Rgene Corporation | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type
    |
    cisplatin • pemetrexed
    5d
    Regional variations in molecular testing and treatment of patients with metastatic NSCLC in the Netherlands. (PubMed, Lung Cancer)
    The application of molecular testing in metastatic non-squamous NSCLC varies across regions in the Netherlands, while minimal variation was observed in the application of targeted therapy. These findings highlight the need for better collaboration between regions to optimize guidelines and ensure uniform care.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    5d
    RAMOSE: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Xiuning Le | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab)
    5d
    SOHO-02: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (clinicaltrials.gov)
    P3, N=444, Recruiting, Bayer | N=174 --> 444
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Hyrnuo (sevabertinib)
    7d
    A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)
    7d
    Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    7d
    TROPION-Lung17: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=400, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    docetaxel • Datroway (datopotamab deruxtecan-dlnk)